GoodRx Holdings, Inc. (NASDAQ:GDRX) Stock Position Raised by Barclays PLC

Barclays PLC boosted its holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 1,316.1% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 140,113 shares of the company’s stock after acquiring an additional 130,219 shares during the period. Barclays PLC’s holdings in GoodRx were worth $973,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. nVerses Capital LLC acquired a new stake in shares of GoodRx during the 3rd quarter worth approximately $33,000. Plato Investment Management Ltd bought a new position in GoodRx during the 2nd quarter worth $43,000. XTX Topco Ltd increased its position in GoodRx by 42.4% in the second quarter. XTX Topco Ltd now owns 29,560 shares of the company’s stock worth $231,000 after buying an additional 8,801 shares during the period. Canada Pension Plan Investment Board lifted its stake in GoodRx by 5.9% in the second quarter. Canada Pension Plan Investment Board now owns 166,142 shares of the company’s stock valued at $1,296,000 after buying an additional 9,200 shares during the last quarter. Finally, EP Wealth Advisors LLC acquired a new position in shares of GoodRx during the third quarter valued at $73,000. 63.77% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

GDRX has been the topic of several recent research reports. Mizuho began coverage on shares of GoodRx in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 price objective on the stock. KeyCorp reduced their price objective on GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Morgan Stanley decreased their price objective on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Barclays cut their target price on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Finally, Citigroup decreased their price target on GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a research note on Friday, January 10th. Five investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.38.

GoodRx Price Performance

Shares of NASDAQ GDRX opened at $4.15 on Wednesday. GoodRx Holdings, Inc. has a twelve month low of $4.09 and a twelve month high of $9.26. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The firm has a 50-day moving average of $4.65 and a two-hundred day moving average of $6.50. The company has a market capitalization of $1.58 billion, a price-to-earnings ratio of -138.33, a PEG ratio of 3.43 and a beta of 1.27.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.